IDH-mutant glioma
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
Phase 1 included.
Clear filters15 of 15 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
Alliance 1
Registry, Oct 31, 2029
ECOG-ACRIN 1
Registry, Dec 31, 2026
GEINO 1
TuvusertibPhase 2
Registry, Sep 2028
German Cancer Research Center 1
Registry, Dec 31, 2032
Hospices Civils de Lyon (OLAGLI) 1
OlaparibPhase 2
Registry, Jan 2027
Hutchmed 1
HMPL-306 (ranosidenib)Phase 3
Registry, Dec 2026
Massachusetts General Hospital 2
NiraparibPhase 1
No dated milestone in 2025 to 2030
Registry, Jan 2027
National Cancer Institute 1
NivolumabPhase 2
No dated milestone in 2025 to 2030
Nuvation Bio 1
FDA Fast Track granted, Aug 20, 2026Registry, Dec 2028
Rigel 1
OlutasidenibPhase 2
Registry, Jun 2029
Servier 2
VorasidenibApproved
SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026Registry, Aug 2027
IvosidenibPhase 1
No dated milestone in 2025 to 2030
University of California, San Francisco 1
Pamiparib + TemozolomidePhase 1
No dated milestone in 2025 to 2030
University of Pennsylvania (Stephen Bagley) 1
Registry, Jun 2027